SDHB and gastrointestinal stromal tumor: Among the trials currently enrolling, one is selectively enrolling STS and GIST patients: in this trial, rogaratinib, an FGFR1-4 TKI, will be tested in patients with sarcomas harboring alterations in FGFR1-4 identified by next-generation sequencing profiling, and in patients with advanced SDH-deficient GIST (NCT04595747).